GLP-1 drugs

The rise of cash-pay GLP-1 prescriptions, fueled by programs like LillyDirect, is generating plenty of buzz—but JPMorgan analyst Lisa C. Gill isn't convinced this is a major shake-up for the healthcare supply chain. According to Gill, while Eli Lilly And Co's (NYSE:LLY) direct-to-consumer push is...

Novo Nordisk AS (NYSE:NVO) will report third-quarter earnings on Wednesday. Wall Street expects 88 cents in EPS and $10.49 billion in revenues when the company reports after market hours. The stock is up 8.55% over the last year and 7.45% year-to-date. Let’s look at what the charts indicate...

Viking Therapeutics Inc. (NASDAQ:VKTX) is set to report its third-quarter earnings on Wednesday, after the market closes. The anticipation is palpable, especially as the stock has skyrocketed almost 240% year-to-date, largely due to excitement surrounding its weight-loss drug candidate, VK2735. As...

Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday after the U.S. Food and Drug Administration said it would reconsider a decision barring drug compounders from selling their own versions of blockbuster weight loss drugs. What Happened: The FDA on Friday said in a court filing...

JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics Inc (NASDAQ:VKTX) with an Overweight rating and a December 2025 price target of $80, which implies a potential 45% upside from its current price of $54.65. At the core of this bullish outlook is Viking’s obesity drug...

In a recent tweet, Bernie Sanders (I-Vt.) criticized the pricing of a popular diabetes drug, Ozempic, and its manufacturer, Novo Nordisk A/S (NYSE:NVO). What Happened: Sanders took to X, formerly Twitter, on Wednesday to express his concerns about the pricing of Ozempic. He suggested that the drug...

The recently launched Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM) is gaining traction among investors, primarily due to its significant holdings in pharmaceutical giants Eli Lilly and Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO). These two companies are at the forefront of the burgeoning...

Mangoceuticals, Inc. (NASDAQ:MGRX) shares are trading higher Tuesday after the company announced the development of oral formulations of Semaglutide and Tirzepatide. The Details: Mangoceuticals announced the development of proprietary oral formulations of Semaglutide (“Slim”) and...

Stocks made new record highs, with the S&P 500 reaching a closing high of 5,137.08 and an intraday high of 5,140.33 on Friday. For the week, the S&P gained 1%. The index is now up 7.7% year to date and up 43.6% from its October 12, 2022 closing low of 3,577.03. In the markets and the...

Eli Lilly and Co. (NYSE:LLY) could witness a 140% surge in its shares, as predicted by Goldman Sachs. The growth is anticipated to be driven by an increased demand for GLP-1 weight loss and diabetes drugs. What Happened: Goldman Sachs’ latest research suggests a bright future for Eli Lilly,...

Congressman Bernie Sanders (I-Vt.) has been known to tussle with public companies over their high prices or anticompetitive behavior, including pharmaceutical companies and their high costs. In his newest battle, Sanders is taking on the growing popularity of weight-loss drugs and diabetes...

What Happened: Jim Cramer outlined fresh investment prospects on Monday, revolving around the growing demand for GLP-1 drugs, typically administered for diabetes and obesity treatment. As reported by CNBC, investors initially expressed concerns about these drugs’ market impact. However, with...

A new study could save hundreds of thousands of lives in the United States each year. New research from Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) found semaglutide (known under the names Wegovy, Ozempic and Rybelsus) can cut the risk of heart attack in overweight patients by 20%. Couple...

Ozempic, Wegovy and Mounjaro could very well have become the most sought-after weight-loss drugs of the past two years, as press reports and social media amplification help push these new medications as a new "miracle treatment" for weight management. A February analysis by Jefferies puts...